Shares of Bionano Genomics (BNGO) experienced a rollercoaster ride, ultimately surging 7.30% over a 24-hour period on Tuesday. This dramatic movement came in the wake of the company's announcement of a $10 million public offering, which initially sent the stock plummeting during regular trading hours.

During the intraday session, BNGO shares nosedived by 38%, hitting a 52-week low of $1.50. The sharp decline was triggered by the company's pricing of a public offering consisting of 5 million shares, along with Series E and short-term Series F warrants, at a combined public offering price of $2.00 per share. This move, aimed at raising approximately $10 million in gross proceeds, initially spooked investors concerned about potential dilution.

However, the tide turned in after-hours trading as some investors appeared to view the steep drop as a buying opportunity. The stock rebounded significantly, gaining 5.06% in extended trading. Bionano Genomics stated that it intends to use the proceeds from the offering for working capital and general corporate purposes, which could potentially strengthen its financial position. As the market continues to digest this information, it remains to be seen whether this momentum can be sustained in upcoming trading sessions. The completion of the offering is expected to occur on or about Wednesday, adding another layer of anticipation to the stock's near-term performance.